cancer panel

Investigators from several centers outlined tumor features, treatment strategies, and clinical trial classifications coming from tumor-germline clinical sequencing programs.

Farsight Genome Systems is touting the rapid scalability of its analytic pipeline as it seeks to make its technology "future-proof" for clinical genomics labs.

Chugai, a member of the Roche Group, has already filed for regulatory approval of FoundationOne CDx with Japan's Ministry of Health, Labor, and Welfare.

The company plans to grow its business based on the FDA approval and preliminary national coverage determination for its FoundationOne CDx test last year. 

For full-year 2017, the company reported $152.9 million in revenues, up 31 percent over 2016.

At the Precision Medicine World Conference, Invitae executives noted that early experience in the genetic screening pilot found more people received positive results than previously expected.

Under the agreement, new companion diagnostics will be included in updates to FoundationOne CDx, which was recently FDA approved.

Over the next three years, Immunovia and its partners will use the firm's Immray PanCan-d assay to screen 6,000 diabetes patients for pancreatic cancer.

A Mount Sinai team performed targeted sequencing on non-small cell lung cancer samples to find mutations with clinical implications.

BioSequence is looking to raise the profile of its genomic offering among clinicians, and to strengthen its case for reimbursement.

 

Pages

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.